Abstract:It is well established that regular use of aspirin can reduce the relative risk of developing colorectal cancer. However, the impact of aspirin on survival after colorectal cancer diagnosis is not well understood. Studies have shown conflicting results. In this population‐based cohort study, the largest one to date, of all patients diagnosed with colorectal cancer in 2007‐2016, we found that aspirin was not associated with neither overall, colorectal cancer‐specific or disease‐free survival. Background Results from previous studies indicate that use of aspirin may improve colorectal cancer (CRC) survival. The aim of this study was to assess whether use of aspirin influences overall survival or CRC‐specific survival in an unselected cohort of patients diagnosed with CRC. Methods The study was performed using the Colorectal Cancer Data Base Sweden (CRCBaSe), a mega‐linkage originating from the Swedish Colorectal Cancer Register, with additional linkages to other national health care registers. All patients diagnosed with primary CRC stage I–III treated with curative surgery, aged 18–85 years at diagnosis, from 2007 through 2016 were identified. Information on low‐dose aspirin use was extracted from the Swedish Prescribed Drug Register. Exposure was defined as dispensed prescription for at least 6 months. Aspirin exposure was analyzed at the time of surgery (yes/no) and as a time‐varying exposure during follow‐up. Follow‐up was restricted to a maximum 6 years, to model 5‐year survival. Cox regression models were fitted to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). Adjustments were performed for sex, age, year of diagnosis, Charlson comorbidity index, hypertension, and ASA score as potential confounders. Results A total of 32,195 patients diagnosed with CRC were included. 6764 (21%) were exposed to aspirin at the time of CRC surgery. The median time of follow‐up was 4.2 years. Aspirin use at the time of surgery was not associated with all‐cause (adjusted HR = 1.03, 95% CI: 0.97–1.08) nor CRC‐specific mortality (adjusted HR = 0.99, 95% CI: 0.91–1.07). Aspirin use during follow‐up was associated with increased all‐cause (adjusted HR = 1.09, 95% CI: 1.04–1.15) but not CRC‐specific mortality (adjusted HR = 0.98, 95% CI: 0.91–1.06). A CRC‐specific effect associated with aspirin was noted from approximately 3 years following surgery. Conclusions In this large nation‐wide cohort study there was no convincing association between aspirin use after CRC and OS or CRC‐specific survival.

Prediagnostic use of low‐dose aspirin and risk of incident metastasis and all‐cause mortality among patients with colorectal cancer

Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis

Low‐dose aspirin use and colorectal cancer survival in 32,195 patients—A national cohort study

Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study

Exploring the Protective Role of Aspirin Use in Mitigating Colorectal Cancer (CRC) Metastasis: A Nationwide Analysis (2016 to 2020)

Timing of Aspirin Use among Patients with Colorectal Cancer in Relation to Mortality: A Systematic Review and Meta-Analysis

Does low-dose aspirin use for cardiovascular disease prevention reduce colorectal cancer deaths? A comparison of two cohorts in the Florence district, Italy

Low-dose aspirin and prevention of colorectal cancer: evidence from a nationwide registry-based cohort in Norway

New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case–control study in UK general practice

Low‐dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin

Risk of lower gastrointestinal bleeding and colorectal neoplasms following initiation of low-dose aspirin: a Danish population-based cohort study

Association of prophylactic low-dose aspirin use with all-cause and cause-specific mortality in cancer patients

IMMUNOREACT 7: Regular aspirin use is associated with immune surveillance activation in colorectal cancer

The role of low-dose aspirin in the prevention of colorectal cancer

Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study

Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview

Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials

Suppressive Effects of Metformin on Colorectal Adenoma Incidence and Malignant Progression

A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma

Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis

Risks of Colorectal Neoplasms and Cardiovascular Thromboembolic Events after the Combined Use of Selective COX-2 Inhibitors and Aspirin with 5-Year Follow-Up: a Meta-Analysis